Citations 2
Melphalan in Multiple Myeloma
Hoogstraten, Barth, Sheehe, Paul R., Cuttner, Janet, Cooper, Talbert, Kyle, Robert A. , Oberfield, Richard A., Townsend, Stuart R., Harley, John B. , Hayes, Donald M., Costa, Giovanni, Holland, James F., HARLEY, JOHN B.
Blood | October 12, 2019 | Volume: 30 | Issue: 1 | Pages: 74-83
Abstract 1. A group of 64 myeloma patients was given a loading dose of Melphalan, 0.15 mg./Kg./Dx7. This was followed by a rest period to allow bone marrow recovery to occur, after which maintenance therapy with a maximum of 0.05 mg./Kg./D was started. 2. To obtain good results, drug doses were required which produced significant bone marrow depression. 3. Subjective improvement was noticed in about 65 per cent of patients; objective improvement, in 78 per cent. 4. Fifty-five per cent of the patients had a response as defined in this study. 5. No difference in survival was found between males and females, nor between patients with Bence Jones proteinuria and those without. 6. Patients who have been on treatment for 3 months and were then found to be responders lived longer than similarly treated patients classified as nonresponders.
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
Ellison, Rose Ruth, Holland, James F., Weil, Marise, Jacquillat, C, Boiron, M, Bernard, Jean, Sawitsky, Arthur, Rosner, Fred, Gussoff, Bernard D., Silver, Richard T. , Karanas, Arthur, Cuttner, Janet, Spurr, Charles L., Hayes, Donald M., Leone, Louis A. , Haurani, Farid I., Kyle, Robert A. , Forcier, R. Jackson, Moon, John H., BLOM, JOHANNES, HUTCHINSON, J. L.
Blood | October 12, 2019 | Volume: 32 | Issue: 4 | Pages: 507-523
Abstract Arabinosyl cytosine (ara-C), a synthetic pyrimidine nucleoside related to the normal metabolites cytidine and deoxycytidine, has been found capable of producing marrow remission at tolerable doses in acute myelocytic and acute lymphocytic leukemia in adults. There were 16 per cent remissions complete in all aspects, 3 per cent complete except for hemoglobin level, and 6 per cent partial remissions among 180 adults with acute myelocytic leukemia treated with any one of 8 variants of infusion duration or daily dose of ara-C. Twenty-four per cent of 37 adults with acute lymphocytic or unclassified leukemia had complete or partial remissions. The comparison of 1, 4, 12 and 24 hours infusion of ara-C (to total dose tolerated) does not show significant superiority for any one group. The complete remission rate with 1 or 12 hour infusions, however, is 25 per cent (superior to that obtained with 6-mercaptopurine) and the recommended schedule of treatment for ara-C based on these data is, therefore, daily infusions of 100 or 50 mg./m.2 in one hour for approximately 3 to 6 weeks followed by maintenance therapy of once weekly subcutaneous injection of 30 mg./m.2 of ara-C. Platelet transfusions should be available when ara-C is used.